Hulio Purple Book BLA 761154

BLA number
761154
Proprietary names
Hulio
Proper names
adalimumab-fkjp
Applicant
Biocon Biologics Inc.
Center
CDER
First observed release
2020-07-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Hulioadalimumab-fkjp351(k) Interchangeable40MG/0.8MLInjectionSubcutaneousAutoinjectorRxLicensed2020-07-06
002Hulioadalimumab-fkjp351(k) Interchangeable40MG/0.8MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2020-07-06
003Hulioadalimumab-fkjp351(k) Interchangeable20MG/0.4MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2020-07-06

Reference Biological Product#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125057Humiraadalimumab351(a)Rx2026-06-01

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2025-02-01U001Hulio351(k) InterchangeableRxBiocon Biologics Inc.
2025-02-01U002Hulio351(k) InterchangeableRxBiocon Biologics Inc.
2025-02-01U003Hulio351(k) InterchangeableRxBiocon Biologics Inc.
2025-01-01U001Hulio351(k) InterchangeableRxBiocon Biologics Inc.
2025-01-01U002Hulio351(k) InterchangeableRxBiocon Biologics Inc.
2025-01-01U003Hulio351(k) InterchangeableRxBiocon Biologics Inc.
2024-01-01U001Hulio351(k) BiosimilarRxBiocon Biologics Inc.
2024-01-01U002Hulio351(k) BiosimilarRxBiocon Biologics Inc.
2024-01-01U003Hulio351(k) BiosimilarRxBiocon Biologics Inc.
2020-07-01N001Hulio351(k) BiosimilarRxMylan Pharmaceuticals Inc.
2020-07-01N002Hulio351(k) BiosimilarRxMylan Pharmaceuticals Inc.
2020-07-01N003Hulio351(k) BiosimilarRxMylan Pharmaceuticals Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2025-01-01001Hulio351(k) InterchangeableRxLicensed2020-07-06
2025-01-01002Hulio351(k) InterchangeableRxLicensed2020-07-06
2025-01-01003Hulio351(k) InterchangeableRxLicensed2020-07-06
2020-07-01001Hulio351(k) BiosimilarRxLicensed2020-07-06
2020-07-01002Hulio351(k) BiosimilarRxLicensed2020-07-06
2020-07-01003Hulio351(k) BiosimilarRxLicensed2020-07-06